Zoetis Commercial United States

Ad Creative: A Librela bedinvetmab injection Story Taffy An Actual Librela Patient

Zoetis A Librela bedinvetmab injection Story Taffy An Actual Librela Patient Ad Commercial Brand Imagery Photoshoot 0
Zoetis A Librela bedinvetmab injection Story Taffy An Actual Librela Patient Ad Commercial Brand Imagery Photoshoot 1
Zoetis A Librela bedinvetmab injection Story Taffy An Actual Librela Patient Ad Commercial Brand Imagery Photoshoot 2

Zoetis Ad Profile

  • Advertising Market: United States
  • Advertiser Industry: Pet
  • Advertiser Category: Health
  • Ad Launch Date: 2025-03-19
  • Ad Format: 30 seconds
  • Ad Description: A Librela bedinvetmab injection Story Taffy An Actual Librela Patient

Zoetis Ad Transcript

Creative storyline based on voiceover.

  • 00:00 - [Music]
  • 00:02 - Li Taffy is a traveling dog she just
  • 00:05 - loves to go her hip pain showed up when
  • 00:08 - we would go on walks she was diagnosed
  • 00:10 - with osteoarthritis pain our
  • 00:12 - veterinarian recommended that we try
  • 00:14 - lella veterinary professionals
  • 00:16 - administering lella who are pregnant
  • 00:18 - trying to conceive or breastfeeding
  • 00:19 - should take extreme care to avoid self
  • 00:21 - injection which can cause allergic
  • 00:23 - reactions like anaphylaxis she's got
  • 00:25 - energy to do things that she wasn't
  • 00:26 - doing before and that's just amazing

Zoetis Ad Visuals

Visual objects featured in the creative imagery.

Zoetis Ad Reach

Audience reach based on YouTube views benchmarked against Market, Industry and Category.

  Medium vs. United States

  Medium vs. Pet

  Medium vs. Health

Zoetis Ad Favorability

Creative favorability based on YouTube likes benchmarked against Market, Industry and Category.

  No Data

  No Data

  No Data

Zoetis Ad Engagement

Audience engagement based on YouTube comments benchmarked against Market, Industry and Category.

  No Data

  No Data

  No Data

Zoetis Ad Collections

Check out similar ads from competitors.